Development of Polypeptide-based Nanoparticles for Non-viral Delivery of CD22 RNA Trans-splicing Molecule as a New Precision Medicine Candidate Against B-lineage ALL

[1]  Rujing Zhang,et al.  Redox-responsive, reversibly-crosslinked thiolated cationic helical polypeptides for efficient siRNA encapsulation and delivery. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[2]  F. Uckun,et al.  CD22ΔE12 as a molecular target for RNAi therapy , 2015, British journal of haematology.

[3]  F. Uckun,et al.  Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in Mice☆ , 2015, EBioMedicine.

[4]  Qiu Zhao,et al.  Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo , 2015, Scientific Reports.

[5]  R. Rose,et al.  Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia. , 2015, The Journal of clinical investigation.

[6]  R. Rose,et al.  Low Dose Total Body Irradiation Combined With Recombinant CD19-Ligand × Soluble TRAIL Fusion Protein is Highly Effective Against Radiation-resistant B-precursor Acute Lymphoblastic Leukemia in Mice , 2015, EBioMedicine.

[7]  L. Mitchell,et al.  CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule. , 2015, Integrative biology : quantitative biosciences from nano to macro.

[8]  F. Uckun,et al.  A Previously Unknown Unique Challenge for Inhibitors of SYK ATP-Binding Site: Role of SYK as A Cell Cycle Checkpoint Regulator , 2014, EBioMedicine.

[9]  F. Uckun,et al.  A rationally designed nanoparticle for RNA interference therapy in B-lineage lymphoid malignancies , 2014, EBioMedicine.

[10]  J. McCubrey,et al.  Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential , 2014, Leukemia.

[11]  Hua Lu,et al.  Maximizing gene delivery efficiencies of cationic helical polypeptides via balanced membrane penetration and cellular targeting. , 2014, Biomaterials.

[12]  J. Falkenburg,et al.  Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia , 2013, PloS one.

[13]  Lichen Yin,et al.  Non‐Viral Gene Delivery via Membrane‐Penetrating, Mannose‐Targeting Supramolecular Self‐Assembled Nanocomplexes , 2013, Advanced materials.

[14]  Qiuhao Qu,et al.  Supramolecular self-assembled nanoparticles mediate oral delivery of therapeutic TNF-α siRNA against systemic inflammation. , 2013, Angewandte Chemie.

[15]  F. Uckun,et al.  Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia. , 2013, Blood.

[16]  M. Relling,et al.  Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? , 2012, Blood.

[17]  Fei Wang,et al.  Reactive and bioactive cationic α-helical polypeptide template for nonviral gene delivery. , 2012, Angewandte Chemie.

[18]  G. Reaman,et al.  CD22 Exon 12 deletion is a characteristic genetic defect of therapy‐refractory clones in paediatric acute lymphoblastic leukaemia , 2012, British journal of haematology.

[19]  M. Relling,et al.  Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. , 2011, Blood.

[20]  Yao Lin,et al.  Ionic polypeptides with unusual helical stability. , 2011, Nature communications.

[21]  F. Uckun,et al.  CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia , 2010, Proceedings of the National Academy of Sciences.

[22]  James R. Anderson,et al.  Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group. , 2008, Seminars in oncology.

[23]  David Steele,et al.  Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  L. Mitchell,et al.  Gene Therapy Progress and Prospects: Reprograming gene expression by trans-splicing , 2005, Gene Therapy.

[25]  R. Crystal,et al.  Trans-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency , 2004, Nature Medicine.